FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Vexler Vladimir				Co	2. Issuer Name <b>and</b> Ticker or Trading Symbol Coherus BioSciences, Inc. [ CHRS ]								ck all applic Directo	able) r (give title	g Pers	son(s) to Iss 10% Ov Other (s below)	/ner		
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)							Chief Scientific Officer							
COHERUS BIOSCIENCES, INC.				101/	01/11/2021														
333 TWIN DOLPHIN DRIVE, SUITE 600																			
(Street)  REDWOOD  CA  94065				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person							
CITY															Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Code (	Transaction Disposed Of (D) (Instr. 3, 4				5. Amour Securitie Beneficia Owned F Reported	es For ally (D) Following (I) (		rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	Amount (A) or (D)		Price	Transact (Instr. 3 a	ion(s)			(IIISti. 4)
Common Stock 01/11/				/2021 A 31,250 <sup>(1)</sup> A		\$0.00	00 65,146 <sup>(2)</sup>			D									
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exerciprice of Price of Derivative Security			3A. Deemed Execution Dat if any (Month/Day/Ye	Date, T	Transac Code (I		of I		Expiratio	6. Date Exercisable and Expiration Date (Month/Day/Year)			nd Am ities ng e Sec and 4)	urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nui of	mber ares					
Stock Option (Right to Buy)	\$17.58	01/11/2021			A		62,500		(3)		01/11/2031	Common Stock	62	,500	\$0.00	62,500	)	D	

## **Explanation of Responses:**

- 1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 11 of each year, with the first 1/3 vesting on January 11, 2022 and with the RSUs being fully vested on January 11, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
- 2. Includes 52,083 RSUs.
- 3. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ Jean-Frederic Viret, as Attorney-in-Fact for Vladimir

01/13/2021

<u>Vexler</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.